Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Basik

Showing results (81-90 of 130) with videos related to

Pageof 13
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2009
Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent mannerMoutih Rafei, Philippe M Campeau, Adriana Aguilar-Mahecha, et al.
Annals of Surgical Oncology|November 10, 2025
ASO Visual Abstract: Uptake of Risk Reducing Mastectomy in Older BRCA1/2 and PALB2 Carriers Undergoing Genetic Testing After 60 Years of AgeAmel Melanson, Sarah Mashal, Carla Apostolova, et al.
Annals of Surgical Oncology|September 25, 2025
Uptake of Risk Reducing Mastectomy in Older BRCA1/2 and PALB2 Carriers Undergoing Genetic Testing after 60 Years of AgeAmel Melanson, Sarah Mashal, Carla Apostolova, et al.
Analytical Chemistry|July 29, 2021
Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker ControversySahar Ibrahim, Cathy Lan, Catherine Chabot, et al.
Nature Communications|July 1, 2018
Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional programAlison Hirukawa, Harvey W Smith, Dongmei Zuo, et al.
Cancer Research|August 23, 2015
The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast CancersStéphanie Légaré, Luca Cavallone, Aline Mamo, et al.
Breast Cancer Research and Treatment|March 19, 2021
A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006)Laila A Gharzai, Lauren A Szczygiel, Dean A Shumway, et al.
Hereditary Cancer in Clinical Practice|April 24, 2025
Chemotherapy receipt in affected BRCA1/2 and PALB2 carriers with operable breast cancer: the impact of early detection and pre-diagnostic awareness on clinical outcomes and treatmentStephanie M Wong, Carla Apostolova, Amina Ferroum, et al.
Nature Communications|May 16, 2019
An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapyCedric Darini, Nour Ghaddar, Catherine Chabot, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 29, 2017
The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experienceAdriana Aguilar-Mahecha, Josiane Lafleur, Manuela Pelmus, et al.
Pageof 13

Showing results (81-90 of 130) with videos related to

Sort By:
Pageof 13
Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2009
Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent mannerMoutih Rafei, Philippe M Campeau, Adriana Aguilar-Mahecha, et al.
Annals of Surgical Oncology|November 10, 2025
ASO Visual Abstract: Uptake of Risk Reducing Mastectomy in Older BRCA1/2 and PALB2 Carriers Undergoing Genetic Testing After 60 Years of AgeAmel Melanson, Sarah Mashal, Carla Apostolova, et al.
Annals of Surgical Oncology|September 25, 2025
Uptake of Risk Reducing Mastectomy in Older BRCA1/2 and PALB2 Carriers Undergoing Genetic Testing after 60 Years of AgeAmel Melanson, Sarah Mashal, Carla Apostolova, et al.
Analytical Chemistry|July 29, 2021
Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker ControversySahar Ibrahim, Cathy Lan, Catherine Chabot, et al.
Nature Communications|July 1, 2018
Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional programAlison Hirukawa, Harvey W Smith, Dongmei Zuo, et al.
Cancer Research|August 23, 2015
The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast CancersStéphanie Légaré, Luca Cavallone, Aline Mamo, et al.
Breast Cancer Research and Treatment|March 19, 2021
A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006)Laila A Gharzai, Lauren A Szczygiel, Dean A Shumway, et al.
Hereditary Cancer in Clinical Practice|April 24, 2025
Chemotherapy receipt in affected BRCA1/2 and PALB2 carriers with operable breast cancer: the impact of early detection and pre-diagnostic awareness on clinical outcomes and treatmentStephanie M Wong, Carla Apostolova, Amina Ferroum, et al.
Nature Communications|May 16, 2019
An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapyCedric Darini, Nour Ghaddar, Catherine Chabot, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 29, 2017
The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experienceAdriana Aguilar-Mahecha, Josiane Lafleur, Manuela Pelmus, et al.
Pageof 13